Acorda acquires NeurogesX's pain patch and liquid for up to $12M

04/18/2013 | American City Business Journals

NeurogesX sold its Qutenza pain patch and an investigational liquid formulation called NGX-1998 to Acorda Therapeutics. NeurogesX will receive $7 million upfront, an additional $2 million if NGX-1998 wins FDA approval plus $3 million contingent on the drug's first-year sales hitting $100 million. The deal does not cover Europe, the Middle East or Africa, where Astellas Pharma holds marketing rights.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR